MRNA therapy hopes to control copper buildup in wilson disease
NCT ID NCT07240896
First seen Nov 21, 2025 · Last updated May 04, 2026 · Updated 18 times
Summary
This early-stage trial tests a new medicine called DSL101 for Wilson disease, a genetic condition that causes copper buildup in the body. The study will give the drug through an IV to 18 adults to check if it is safe and helps control copper levels. The goal is to manage the disease, not cure it, and participants will still need ongoing care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSONS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.